| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Nivolumab plus ipilimumab |
| Brand | Opdivo® plus Yervoy® |
| Indication | For the treatment of advanced melanoma. |
| Assessment Process | |
| Rapid review commissioned | 27/06/2016 |
| Rapid review completed | 07/11/2016 |
| Rapid review outcome | Reimbursement Not Recommended at the Submitted Price. |
The HSE has approved reimbursement following confidential price negotiations October 2017.